

# Wasteful and Inappropriate Service Reduction (WISeR) Model Office Hour

---

Center for Medicare and Medicaid Innovation

July 17, 2025

Centers for Medicare & Medicaid Services | Center for Medicare & Medicaid Innovation





## DIAL IN

---

It is recommended that you listen via your computer speakers.

### **Options for audio listening:**

**Dial-In (US):** +1 929 436 2866 or  
+1 669 900 6833

**Webinar ID:** 964 9194 8643

**ID/Passcode:** 481601



## CAPTIONS

---

Closed captioning is available at the bottom of the screen.




## SHARE FEEDBACK

---


Please complete a short survey that will be available at the end of the event.


# Office Hour Format

 In today's office hour, we will answer:

 **Common questions** submitted to our help desk and via **registration forms**

 **Live questions from participants** on the call


 Please type your questions in the **Q&A box**.

 If we do not get to your question, we welcome you to email the WISeR team at [WISeR@cms.hhs.gov](mailto:WISeR@cms.hhs.gov). We will aim to answer any unaddressed questions via emails and upcoming FAQs.


# On Today's Call



**Claire Kihn**  
*WISeR Team Lead,  
CMS Innovation Center*



**Alexandra Chong**  
*Deputy Division Director,  
CMS Innovation Center*



**Kate Blackwell**  
*Division Director,  
CMS Innovation Center*

# CMS Remarks

---

# Model Overview

---

# Model Overview



**PROBLEM:** Wasteful medical care spending accounts for an estimated **25% of total healthcare spending** with a substantial portion being attributable to fraud, waste (including low-value services), and abuse (FWA).

- Original Medicare spent between **\$1.9 to \$5.8 billion on low value services** in 2022.



**SOLUTION:** Implement a 6-year model with **companies that apply emerging technologies to clinical and claims processing solutions** as model participants to provide improved and expedited prior authorization processes for selected services in specific geographic areas in Original Medicare. **Leverage enhanced technologies** to ensure timely and appropriate Medicare payment for select services, streamline prior authorization processes, and help patients avoid unnecessary or inappropriate care.



Technology-Enabled Prior Authorization Tools and Processes



Select list of services vulnerable to fraud waste, and abuse or inappropriate use under Original Medicare



Navigation of beneficiaries away from potentially low-value and inappropriate services



Reductions in delivery of fraudulent and wasteful services



Reductions in spending on fraudulent and wasteful services

# High-Level Model Parameters



6-year voluntary model (two 3-year agreement periods)



Application of prior authorization to a select set of services that have been identified as potentially vulnerable to fraud, waste, and abuse, and/or inappropriate use



Applies to all providers/suppliers in selected geographic areas serving Original Medicare beneficiaries



Companies specializing in enhanced technologies to improve and expedite the prior authorization process as model participants



Model participants receive a portion of averted costs that can be attributed to their reduction of wasteful or inappropriate care for each selected service under the model.



Performance metrics focus on prior authorization processing times and provider/supplier experience with prior authorization. Beneficiary experience and clinical quality outcomes will also be monitored/evaluated.



# Impacted Providers and Suppliers and Model Participants

## Medicare Providers & Suppliers



- ✓ All providers and suppliers in the selected geographic areas who are delivering services to Original Medicare beneficiaries
- ✓ Have the option to submit prior authorization requests and receive prior authorization determination for the model's selected services via streamlined processes implemented by the model participant and/or the Medicare Administrative Contractor (MAC) operating in the provider's region
- ✓ No change in provider/supplier payments or provider's/supplier's appeal rights

## Technology Companies



- ✓ Demonstrated success in managing the prior authorization processes with enhanced technology for other payers/health plans
- ✓ Demonstrated ability to interpret and apply clinical coverage criteria derived from NCDs and LCDs
- ✓ Ensuring appropriate clinical expertise is incorporated into pre-approval and medical review process protecting and facilitating beneficiary and provider/supplier appeals
- ✓ Compliance with all applicable federal and CMS data protection and security requirements, HIPAA regulations, and other applicable privacy and security laws and CMS policies
- ✓ Capability to offer back-up options to advanced technologies, including phone, fax, electronic portals and regular mail

# Selected MAC Jurisdictions and States

JF (Noridian)

- Arizona
- Washington

JH (Novitas)


- Oklahoma
- Texas

J15 (CGS)

- Ohio

JL (Novitas)

- New Jersey



# Initial Service Selection Criteria



## Leveraging Existing Evidence and Experience

- Services that have existing publicly available coverage requirements specified in statute, regulation, NCD, or LCD
- Services already subject to prior authorization by other payers



## Patient Safety

- Non-emergent services
- Excludes inpatient only services
- Excludes first line diagnostics and treatments for a medical condition
- Prioritize standalone/non-repetitive services



## Opportunity

- Services known to be a source of fraud, waste, or abuse (FWA) or potentially vulnerable to FWA
- Excludes services currently subject to other prior authorization programs
- Sufficient volume of services for evaluability

# Services Included: Performance Year 1 (2026)

Service Category	Associated NCD/LCDs
<b>Stimulator Services</b> <ul style="list-style-type: none"> <li>Electrical Nerve Stimulators</li> <li>Sacral Nerve Stimulation for Urinary Incontinence</li> <li>Phrenic Nerve Stimulator</li> <li>Deep Brain Stimulation for Essential Tremor and Parkinson's Disease</li> <li>Vagus Nerve Stimulation</li> </ul>	NCD 160.7 NCD 230.18 NCD 160.19 NCD 160.24 NCD 160.18
<b>Induced Lesions of Nerve Tracts</b>	NCD 160.1
<b>Epidural Steroid Injections for Pain Management</b>	L39015, L39242, L36920
<b>Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)</b>	L34106, L38201, L35130
<b>Cervical Fusion</b> (Excluding codes already included in OPD)	L39741, L39762, L39793
<b>Arthroscopic Lavage and Arthroscopic Debridement for the Osteoarthritic Knee</b>	NCD 150.9
<b>Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea</b>	L38307, L38312, L38385
<b>Incontinence Control Devices</b>	NCD 230.10
<b>Diagnosis and Treatment of Impotence</b>	NCD 230.4
<b>Percutaneous Image-Guided Lumbar Decompression for Spinal Stenosis</b>	NCD 150.13
<b>Skin and Tissue Substitutes</b> <ul style="list-style-type: none"> <li>Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds</li> <li>Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities</li> </ul>	L35041 L36690

\*CPT codes associated with selected services will be forthcoming.

# Other Key Model Design Elements

## Payment Approach

- No change in provider/supplier payments for services selected for prior authorization under the model
- Model participants are compensated based on a share of averted expenditures rather than on a fixed fee or per-claim basis
- Model payments are calculated from requests that did not result in a paid claim


## Quality and Performance Measurement

- Model participants monitored on metrics related to prior authorization process quality and payment adjustments based on efficiency/accuracy of their processes
- Provider/Supplier and Beneficiary Experience surveys
- Exploring inclusion of broad clinical outcomes that could be impacted by WISeR policies


## Evaluation

- As the model is limited to specific geographic areas, we anticipate comparison of key model metrics and outcomes over time against a matched comparison group to determine the model's impact.
- Key outcomes include:
  - Frequency of delivery and expenditures associated with selected services
  - Utilization of and expenditures on services that are substitutes for the selected services overall expenditures
  - Quality measures associated with the selected services

# WISeR Prior Authorization Process Flow Chart



# Timeline





# Additional Resources

[Model Website](#)

[Request for Applications](#)

[Federal Register Notice](#)

**WISeR Help Desk:** [WISeR@cms.hhs.gov](mailto:WISeR@cms.hhs.gov)





# Open Q&A

Please type your question in the **Q&A box**.

If we do not get to your question, we welcome you to email the WISeR team at [WISeR@cms.hhs.gov](mailto:WISeR@cms.hhs.gov). We will aim to answer unaddressed questions via emails and upcoming FAQs.

# Closing

---



**We appreciate your time and interest!**

Please share your feedback via the survey following this event.

**Questions?** Email [WISeR@cms.hhs.gov](mailto:WISeR@cms.hhs.gov)